Raffles Medical Group Ltd (SGX: BSL) is a private healthcare services provider with operations in Singapore and a number of other Asian countries. In Singapore, the company has its flagship Raffles Hospital. It is also developing two hospitals in the Chinese cities of Chongqing and Shanghai.
In late April, the company reported its 2018 first quarter earnings update. There are both positive and negative takeaways that investors may want to learn about. But first, let’s run through the company’s numbers.
Here’s a condensed income statement from Raffles Medical for 2018’s first quarter:
Source: Raffles Medical 2018 first quarter earnings press release
We can see that Raffles Medical enjoyed a decent quarter, with slow growth in revenue, EBITDA (earnings before interest, taxes, depreciation, and amortisation), operating profit, PATMI (profit after taxes and minority interests), and diluted earnings per share.
Firstly, Raffles Medical had achieved higher revenue for the quarter, driven by top line growth in both its Hospital Services and Healthcare Services divisions. The former benefited from a higher local patient load, while the latter’s revenue growth was due to an increase in the local patient load, as well as a new contract providing air borders screening services.
Secondly, the company generated strong operating cash flow of S$24.0 million during the reporting quarter, up 31.8% from a year ago.
Thirdly, the healthcare services provider ended 2018’s first quarter with a net cash position of S$22.3 million (S$94.0 million in cash and equivalents, and total borrowings of S$71.7 million in total debt). That’s a strong balance sheet.
Lastly, the company is currently undertaking a number of projects that could grow its business over the mid to long term. For example, there’s the extension of its flagship Raffles Hospital which was completed on 22 January 2018 (the extension increased the hospital’s land area by around 80%). Then, there are also the aforementioned Chinese hospitals in Chongqing and Shanghai.
Firstly, in the first quarter of 2018, Raffles Medical’s operating margin declined from 15.8% a year ago to 15.7%, mainly due to higher inventory, depreciation, and staff costs. The company had to spend to meet growing demand from patients.
Secondly, with all its various growth projects ongoing, Raffles Medical’s profit margins in the near future are expected to be compressed, as the projects will require time to scale and be profitable.
How We Made an 88% Return in Just 19 Months!
Members of David Kuo’s personal investing club Stock Advisor Gold were recently rewarded with the biggest winner Motley Fool Singapore has seen to date In a special, 100% FREE report we’ve put together, we take you behind the scenes to show you exactly how we first uncovered this stock… every article and piece of research we released on it… and what ultimately led to our decision to SELL for an 88% gain. Click here to claim your copy now!
The information provided is for general information purposes only and is not intended to be personalised investment or financial advice. Motley Fool Singapore contributor Lawrence Nga doesn’t own shares in any companies mentioned. The Motley Fool Singapore has a buy recommendation on Raffles Medical.